TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Fudan University